<DOC>
	<DOC>NCT03083561</DOC>
	<brief_summary>The main purpose of this study is to evaluate the safety and tolerability of LY3337641 in healthy Japanese and Caucasian participants. The study will also investigate how the body processes LY3337641 and the effect of LY3337641 on the body. The study will last up to 4 weeks for each participant. Screening may occur within 28 days prior to first dose of study drug.</brief_summary>
	<brief_title>A Study of LY3337641 in Japanese and Caucasian Healthy Participants</brief_title>
	<detailed_description />
	<criteria>Overtly healthy Japanese or Caucasian Body mass index (BMI) 18.0 32.0 kilograms per square meter (kg/mÂ²) Are currently enrolled in a clinical trial involving an investigational product or offlabel use of a drug or device or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study Have participated, within the last 30 days, in a clinical trial involving an investigational product. If the previous investigational product has a long halflife, 3 months or 5 halflives (whichever is longer, if known) should have passed Have an abnormality in the 12lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study or affects or confounds the QTc analysis or have Fridericiacorrected QT interval (QTcF) &gt;450 milliseconds (msec) for males and &gt;470 msec for females Have had symptomatic herpes zoster within 3 months of screening Have active or latent tuberculosis (TB) based on a positive medical history, examination, and/or TB test results. Have received live vaccine(s) within 1 month of screening or intend to during the study Are immunocompromised Have a history of constipation or have had acute constipation within 3 weeks prior to admission</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>